Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation

J Mol Cell Cardiol. 2018 Mar:116:5-15. doi: 10.1016/j.yjmcc.2018.01.010. Epub 2018 Feb 3.

Abstract

Phosphorylation at serine 10 (S10) is the major posttranslational modification of the tumor suppressor p27, and is reduced in both human and mouse atherosclerosis. Moreover, a lack of p27-phospho-S10 in apolipoprotein E-null mice (apoE-/-) leads to increased high-fat diet-induced atherosclerosis associated with endothelial dysfunction and augmented leukocyte recruitment. In this study, we analyzed whether p27-phospho-S10 modulates additional endothelial functions and associated pathologies. Defective p27-phospho-S10 increases COX-2 activity in mouse aortic endothelial cells without affecting other key regulators of vascular reactivity, reduces endothelium-dependent dilation, and increases arterial contractility. Lack of p27-phospho-S10 also elevates aortic COX-2 expression and thromboxane A2 production, increases aortic lumen diameter, and aggravates angiotensin II-induced abdominal aortic aneurysm development in apoE-/- mice. All these abnormal responses linked to defective p27-phospho-S10 are blunted by pharmacological inhibition of COX-2. These results demonstrate that defective p27-phospho-S10 modifies endothelial behavior and promotes aneurysm formation via COX-2 activation.

Keywords: Aneurysm; Cox-2; Endothelial cell; Vascular contractility; p27; p27 phosphorylation at serine 10.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Angiotensin II
  • Animals
  • Aorta / pathology
  • Aortic Aneurysm, Abdominal / metabolism*
  • Aortic Aneurysm, Abdominal / physiopathology*
  • Blood Pressure / drug effects
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism*
  • Cyclooxygenase 2 / metabolism*
  • Endothelial Cells / metabolism
  • Enzyme Activation
  • Mice, Inbred C57BL
  • Phosphorylation
  • Phosphoserine / metabolism*
  • Thromboxanes / metabolism
  • Vasodilation
  • Ventricular Remodeling / drug effects

Substances

  • Thromboxanes
  • Angiotensin II
  • Cyclin-Dependent Kinase Inhibitor p27
  • Phosphoserine
  • Cyclooxygenase 2
  • Acetylcholine